Camelot Portfolios’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $411K | Hold |
1,900
| – | – | 0.29% | 126 |
|
|
2026
Q1 | $348K | Hold |
1,900
| – | – | 0.26% | 134 |
|
|
2025
Q4 | $334K | Sell |
1,900
-200
| -10% | -$32.7K | 0.2% | 133 |
|
|
2025
Q3 | $294K | Buy |
+2,100
| New | +$284K | 0.17% | 147 |
|
|
2025
Q2 | – | Sell |
-4,950
| Closed | -$677K | – | 205 |
|
|
2025
Q1 | $677K | Buy |
+4,950
| New | +$708K | 0.42% | 88 |
|
|
2024
Q3 | – | Sell |
-1,900
| Closed | -$440K | – | 188 |
|
|
2024
Q2 | $440K | Buy |
+1,900
| New | +$413K | 0.25% | 100 |
|
|
2024
Q1 | – | Sell |
-2,000
| Closed | -$518K | – | 147 |
|
|
2023
Q4 | $518K | Buy |
2,000
+900
| +82% | +$221K | 0.31% | 95 |
|
|
2023
Q3 | $283K | Sell |
1,100
-1,000
| -48% | -$267K | 0.27% | 103 |
|
|
2023
Q2 | $598K | Buy |
2,100
+1,000
| +91% | +$298K | 0.38% | 78 |
|
|
2023
Q1 | $306K | Buy |
+1,100
| New | +$304K | 0.21% | 127 |
|
|
2022
Q4 | – | Sell |
-2,183
| Closed | -$583K | – | 178 |
|
|
2022
Q3 | $583K | Sell |
2,183
-1,622
| -43% | -$344K | 0.55% | 61 |
|
|
2022
Q2 | $776K | Sell |
3,805
-1,019
| -21% | -$208K | 0.47% | 71 |
|
|
2022
Q1 | $1.02M | Buy |
4,824
+195
| +4% | +$42.4K | 0.51% | 58 |
|
|
2021
Q4 | $1.11M | Buy |
4,629
+679
| +17% | +$175K | 0.45% | 66 |
|
|
2021
Q3 | $1.12M | Sell |
3,950
-246
| -6% | -$80.6K | 0.57% | 51 |
|
|
2021
Q2 | $1.45M | Sell |
4,196
-1,017
| -20% | -$308K | 0.59% | 50 |
|
|
2021
Q1 | $1.46M | Buy |
5,213
+273
| +6% | +$73.6K | 0.61% | 48 |
|
|
2020
Q4 | $1.21M | Buy |
4,940
+673
| +16% | +$174K | 0.63% | 47 |
|
|
2020
Q3 | $1.21M | Sell |
4,267
-478
| -10% | -$133K | 0.76% | 38 |
|
|
2020
Q2 | $1.27M | Sell |
4,745
-252
| -5% | -$75.8K | 0.82% | 35 |
|
|
2020
Q1 | $1.58M | Sell |
4,997
-352
| -7% | -$107K | 0.88% | 29 |
|
|
2019
Q4 | $1.59M | Buy |
5,349
+10
| +0.2% | +$2.77K | 0.67% | 42 |
|
|
2019
Q3 | $1.24M | Sell |
5,339
-70
| -1% | -$16.3K | 0.59% | 49 |
|
|
2019
Q2 | $1.26M | Buy |
5,409
+960
| +22% | +$222K | 0.52% | 60 |
|
|
2019
Q1 | $1.05M | Buy |
4,449
+2,762
| +164% | +$870K | 0.44% | 65 |
|
|
2018
Q4 | $508K | Buy |
1,687
+513
| +44% | +$164K | 0.24% | 116 |
|
|
2018
Q3 | $415K | Sell |
1,174
-531
| -31% | -$183K | 0.19% | 126 |
|
|
2018
Q2 | $495K | Buy |
+1,705
| New | +$479K | 0.21% | 118 |
|
Other funds holding BIIB
Camelot Portfolios's BIIB Position: Q2 2026 in Review
Camelot Portfolios held its Biogen (BIIB) position steady in Q2 2026 at 1,900 shares worth $411K. The position accounts for 0.29% of the portfolio, ranked #126.
Camelot Portfolios first reported a position in BIIB in Q2 2018 and has held it in 28 quarters since. The position peaked at $1.59M in Q4 2019. 1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Camelot Portfolios held 1,900 shares of Biogen worth $411K as of Q2 2026.
- Camelot Portfolios left its Biogen share count unchanged in Q2 2026.
- Biogen made up 0.29% of Camelot Portfolios's portfolio in Q2 2026, its #126 holding.
- Camelot Portfolios first reported a position in Biogen in Q2 2018 and has held it in 28 quarters since.
- Camelot Portfolios's Biogen position peaked at $1.59M in Q4 2019.
- 1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Camelot Portfolios's 13F filing for Q2 2026, filed 17 Jul 2026.